- Home
- ARQT vs DSGR Comparison
ARQT vs DSGR Comparison
Compare ARQT & DSGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- DSGR
- Stock Information
- Founded
- ARQT 2016
- DSGR 1952
- Country
- ARQT United States
- DSGR United States
- Employees
- ARQT N/A
- DSGR N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- DSGR Industrial Machinery/Components
- Sector
- ARQT Health Care
- DSGR Industrials
- Exchange
- ARQT Nasdaq
- DSGR Nasdaq
- Market Cap
- ARQT 1.7B
- DSGR 1.4B
- IPO Year
- ARQT 2020
- DSGR N/A
- Fundamental
- Price
- ARQT $15.99
- DSGR $33.26
- Analyst Decision
- ARQT Strong Buy
- DSGR Buy
- Analyst Count
- ARQT 7
- DSGR 1
- Target Price
- ARQT $19.00
- DSGR $39.00
- AVG Volume (30 Days)
- ARQT 1.8M
- DSGR 61.9K
- Earning Date
- ARQT 08-06-2025
- DSGR 07-31-2025
- Dividend Yield
- ARQT N/A
- DSGR N/A
- EPS Growth
- ARQT N/A
- DSGR N/A
- EPS
- ARQT N/A
- DSGR 0.08
- Revenue
- ARQT $263,464,999.00
- DSGR $1,928,948,000.00
- Revenue This Year
- ARQT $61.83
- DSGR $10.80
- Revenue Next Year
- ARQT $36.55
- DSGR $4.10
- P/E Ratio
- ARQT N/A
- DSGR $361.29
- Revenue Growth
- ARQT 99.50
- DSGR 13.48
- 52 Week Low
- ARQT $8.03
- DSGR $21.87
- 52 Week High
- ARQT $17.75
- DSGR $41.47
- Technical
- Relative Strength Index (RSI)
- ARQT 56.88
- DSGR 66.98
- Support Level
- ARQT $15.43
- DSGR $31.50
- Resistance Level
- ARQT $17.29
- DSGR $32.94
- Average True Range (ATR)
- ARQT 0.97
- DSGR 0.90
- MACD
- ARQT 0.06
- DSGR 0.05
- Stochastic Oscillator
- ARQT 63.70
- DSGR 89.98
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.